Aquestive Therapeutics, Inc.
AQST$207M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWARREN142 employees
Drugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Apr 11, 2026
7wMarket Overview
Stock performance and key metrics
AQST News
Catalyst Timeline
2 upcoming, 2 past
Drug Pipeline
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
Epilepsy
Diazepam Buccal Film 12.5 mg
Epilepsy
Diazepam Buccal Film
Epilepsy
Diastat® Rectal Gel (Valeant Pharmaceuticals USA)
Epilepsy
DESF
Allergic Reaction
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category | Phase 3 | Epilepsy | - | - |
Diazepam Buccal Film 12.5 mg | Phase 2 | Epilepsy | - | - |
Diazepam Buccal Film | Phase 2 | Epilepsy | - | - |
Diastat® Rectal Gel (Valeant Pharmaceuticals USA) | Phase 2 | Epilepsy | - | - |
DESF | Phase 2 | Allergic Reaction | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply